Australien - engelsk - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - naloxone hydrochloride dihydrate, quantity: 440 microgram (equivalent: naloxone hydrochloride?, qty 400 microgram) - injection - excipient ingredients: sodium chloride; water for injections; edetate sodium; hydrochloric acid - naloxone is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, codeine, morphine and heroin, and the mixed opioid agonist-antagonist analgesics such as pentazocine. naloxone is also indicated for the diagnosis of suspected acute opioid overdosage.

USA - engelsk - NLM (National Library of Medicine)

medical purchasing solutions, llc - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride injection, usp is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. naloxone hydrochloride injection, usp is also indicated for diagnosis of suspected or known acute opioid overdosage. naloxone hydrochloride injection, usp may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see clinical pharmacology; adjunctive use in septic shock ). naloxone hydrochloride injection is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients in naloxone hydrochloride injection. naloxone hydrochloride injection is an opioid antagonist. physical dependence associated with the use of naloxone hydrochloride injection has not been reported. tolerance to the opio

USA - engelsk - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride injection, usp is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. naloxone hydrochloride injection, usp is also indicated for diagnosis of suspected or known acute opioid overdosage. naloxone hydrochloride injection, usp may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see clinical pharmacology; adjunctive use in septic shock ). naloxone hydrochloride injection is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients in naloxone hydrochloride injection. naloxone hydrochloride injection is an opioid antagonist. physical dependence associated with the use of naloxone hydrochloride injection has not been reported. tolerance to the opioid antagonist effect of naloxone is not known to occur.

USA - engelsk - NLM (National Library of Medicine)

civica, inc. - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride injection, usp is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. naloxone hydrochloride injection, usp is also indicated for diagnosis of suspected or known acute opioid overdosage. naloxone hydrochloride injection, usp may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see clinical pharmacology; adjunctive use in septic shock ). naloxone hydrochloride injection is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients in naloxone hydrochloride injection. naloxone hydrochloride injection is an opioid antagonist. physical dependence associated with the use of naloxone hydrochloride injection has not been reported. tolerance to the opioid antagonist

Canada - engelsk - Health Canada

omega laboratories limited - naloxone hydrochloride (naloxone hydrochloride dihydrate) - solution - 0.4mg - naloxone hydrochloride (naloxone hydrochloride dihydrate) 0.4mg - opiate antagonists

Canada - engelsk - Health Canada

omega laboratories limited - naloxone hydrochloride (naloxone hydrochloride dihydrate) - solution - 1mg - naloxone hydrochloride (naloxone hydrochloride dihydrate) 1mg - opiate antagonists

Canada - engelsk - Health Canada

sandoz canada incorporated - naloxone hydrochloride (naloxone hydrochloride dihydrate) - solution - 0.4mg - naloxone hydrochloride (naloxone hydrochloride dihydrate) 0.4mg - opiate antagonists

Canada - engelsk - Health Canada

strides pharma canada inc - naloxone hydrochloride (naloxone hydrochloride dihydrate) - solution - 0.4mg - naloxone hydrochloride (naloxone hydrochloride dihydrate) 0.4mg - opiate antagonists

USA - engelsk - NLM (National Library of Medicine)

ij therapeutics, llc - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone auto-injector is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. naloxone auto-injector is intended for immediate administration as emergency therapy in settings where opioids may be present. naloxone auto-injector is not a substitute for emergency medical care. naloxone auto-injector is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients. risk summary the limited available data on naloxone use in pregnant women are not sufficient to inform a drug-associated risk. however, there are risks to the fetus of the opioid-dependent mother with use of naloxone [see clinical considerations] . in animal reproduction studies, no embryotoxic or teratogenic effects were observed in mice and rats treated with naloxone hydrochloride during the period of organogenesis at doses equivalent to 4-times and

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - naloxone hydrochloride dihydrate, quantity: 10.9 mg (equivalent: naloxone hydrochloride?, qty 10 mg); oxycodone hydrochloride, quantity: 20 mg - tablet, modified release - excipient ingredients: magnesium stearate; povidone; macrogol 3350; stearyl alcohol; titanium dioxide; lactose monohydrate; purified talc; polyvinyl alcohol; iron oxide red; ethylcellulose - targin modified release tablet is indicated for the management of severe pain where:,- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and,- the pain is opioid-responsive; and,- requires daily, continuous, long term treatment.,targin modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.,targin modified release tablet is not indicated as an as-needed (prn) analgesia,the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,targin is indicated as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.